The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 2 - 3 µg/ml.
1/16000. This application has only been tested against the recombinant protein.
Use a concentration of 0.1 - 0.3 µg/ml. Predicted molecular weight: 37 kDa.Can be blocked with Human AKR1A1 peptide (ab23210). Approx 37-40kDa band observed in Human Placenta and Liver lysates.
FunctionCatalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4-nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D-glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN).
Tissue specificityWidely expressed. Highly expressed in kidney, salivary gland and liver. Detected in trachea, stomach, brain, lung, prostate, placenta, mammary gland, small intestine and lung.
Sequence similaritiesBelongs to the aldo/keto reductase family.
ab11802 at 2.5µg/ml, staining AKR1A1 in Human Kidney sections by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections). Steamed antigen retrieval with pH 6 citrate buffer was performed, and AP-staining was used.
References for Anti-AKR1A1 antibody (ab11802)
This product has been referenced in:
Singh S et al. SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity. Int J Biochem Cell Biol42:1105-14 (2010).
Read more (PubMed: 20097305) »
Diggle CP et al. Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J Histochem Cytochem57:763-74 (2009).
Read more (PubMed: 19365088) »